- Zymeworks (ZYME, Financial) to announce Q1 2025 financial results on May 8, 2025.
- Conference call and webcast to follow at 4:30 PM ET.
- Zymeworks focuses on novel biotherapeutics for cancer, inflammation, and autoimmune diseases.
Zymeworks Inc. (ZYME), a clinical-stage biotechnology company, is set to release its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, the company will conduct a conference call and webcast at 4:30 PM Eastern Time to discuss its financial performance and provide a corporate update.
Zymeworks specializes in the development of innovative biotherapeutics aimed at treating complex conditions such as cancer, inflammation, and autoimmune diseases. The company has developed zanidatamab, a HER2-targeted bispecific antibody, which has received accelerated approval from the U.S. FDA for treating previously-treated, unresectable or metastatic HER2-positive biliary tract cancer.
The company’s strategic collaborations with global biopharmaceutical firms and its robust pipeline, including Phase 1 studies for ZW171 and ZW191, underline its commitment to advancing therapeutic solutions. Investors and interested parties can access the live webcast and obtain dial-in details through Zymeworks’ website at ir.zymeworks.com/events-and-presentations.
